References
- Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am. J. Ophthalmol.126, 487–497 (1998).
- The Advanced Glaucoma Intervention Study (AGIS) 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am. J. Ophthalmol.130, 429–440 (2000).
- Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression, results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol.120, 1268–1279 (2002).
- Kass MA, Heuer DK, Higginbotham EJ et al. The Ocular Hypertension Treatment Study, a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol.120, 701–713 (2002).
- Lichter PR, Musch DC, Gillespie BW et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology108, 1943–1953 (2001).
- Nouri-Mahdavi K, Hoffman D, Coleman AL et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology111, 1627–1635 (2004).
- Bengtsson B, Leske MC, Hyman L, Heijl A. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology114, 205–209 (2007).
- Caprioli J. Intraocular pressure fluctuation, an independent risk factor for glaucoma? Arch. Ophthalmol.125, 1124–1125 (2007).
- Hong S, Seong GJ, Hong YJ. Long-term intraocular pressure fluctuation and progressive visual field deterioration in patients with glaucoma and low intraocular pressures after a triple procedure. Arch. Ophthalmol.125, 1010–1013 (2007).
- Nakagami T, Yamazaki Y, Hayamizu F. Prognostic factors for progression of visual field damage in patients with normal-tension glaucoma. Jpn J. Ophthalmol.50, 38–43 (2006).
- Sherwood MB, Craven ER, Chou C et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension, a 12-month randomized trial. Arch. Ophthalmol.124, 1230–1238 (2006).
- Spaeth GL, Bernstein P, Caprioli J, Schiffman RM. Control of intraocular pressure and fluctuation with fixed-combination brimonidine–timolol versus brimonidine or timolol monotherapy. Am. J. Ophthalmol.151(1), 93–99.e4 (2011).
- Sommer A, Tielsch JM, Katz J et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch. Ophthalmol.109, 1090–1095 (1991).
- Boyle JE, Ghosh K, Gieser DK, Adamsons IA. A randomized trial comparing the dorzolamide–timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide–Timolol Study Group. Ophthalmology105, 1945–1951 (1998).
- Bell NP, Ramos JL, Feldman RM. Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension. Clin. Ophthalmol.4, 1331–1346 (2010).
- Hong S, Kim CY, Seong GJ. Long-term intraocular pressure fluctuation and visual field progression in glaucoma patients with low intraocular pressure after post-trabeculectomy phacoemulsification. J. Ocul. Pharmacol. Ther.23, 571–576 (2007).
- Day DG, Schacknow PN, Wand M et al. Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol.135, 138–143 (2003).
- Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily, 1-year results in glaucoma patients. Brimonidine Study Group. Am. J. Ophthalmol.127, 20–26 (1999).
- Stewart WC, Stewart JA, Day D, Sharpe ED. Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. Acta Ophthalmol. Scand.81, 242–246 (2003).
- Stewart WC, Stewart JA, Day DG, Sharpe ED, Jenkins JN. Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy. Eye (Lond.)18, 990–995 (2004).
- Konstas AG, Stewart WC, Topouzis F, Tersis I, Holmes KT, Stangos NT. Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma. Am. J. Ophthalmol.131, 729–733 (2001).
- Liu JH, Medeiros FA, Slight JR, Weinreb RN. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy. Ophthalmology116, 449–454 (2009).
- Liu JH, Medeiros FA, Slight JR, Weinreb RN. Diurnal and nocturnal effects of brimonidine monotherapy on intraocular pressure. Ophthalmology117, 2075–2079 (2010).
- Liu JH, Zhang X, Kripke DF, Weinreb RN. Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes. Invest. Ophthalmol. Vis. Sci.44, 1586–1590 (2003).
- Mosaed S, Liu JH, Weinreb RN. Correlation between office and peak nocturnal intraocular pressures in healthy subjects and glaucoma patients. Am. J. Ophthalmol.139(2), 320–324 (2005).
- Stewart WC, Konstas AG, Nelson LA, Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology115(7), 1117–1122.e1 (2005).
- Wax MB, Camras CB, Fiscella RG, Girkin C, Singh K, Weinreb RN. Emerging perspectives in glaucoma, optimizing 24-hour control of intraocular pressure. Am. J. Ophthalmol.133, S1–S10 (2002).
- Barkana Y, Anis S, Liebmann J, Tello C, Ritch R. Clinical utility of intraocular pressure monitoring outside of normal office hours in patients with glaucoma. Arch. Ophthalmol.124, 793–797 (2006).